Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      FDA Clears MiniMed Fit™ -- World's First and Only Tubeless Insulin Pump with Up to Seven-Day Wear and Zero Interruptions

      MiniMed logo

      News provided by

      MiniMed

      Nov 16, 2026, 09:05 ET

      Share this article

      Share this article


      The only tubeless pump with no charging or cartridge changes for up to seven days, combined with a 300-unit insulin capacity and advanced insulin automation

      NORTHRIDGE, Calif., Nov. 16, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) today announced U.S. Food and Drug Administration (FDA) clearance of MiniMed Fit™, the company's first tubeless insulin pump, offering people with diabetes a new differentiated option that combines up to seven days of wear, a 300-unit insulin capacity, app control and proven SmartGuard™ technology.

      Continue Reading
      MiniMed Fit: Everything a tubeless pump should be.
      MiniMed Fit: Everything a tubeless pump should be.
      MiniMed Fit: Everything a tubeless pump should be.
      MiniMed Fit: Everything a tubeless pump should be.
      MiniMed Fit: Everything a tubeless pump should be.
      MiniMed Fit: Everything a tubeless pump should be.
      MiniMed Fit: Everything a tubeless pump should be.
      MiniMed Fit: Everything a tubeless pump should be.
      MiniMed Fit: Everything a tubeless pump should be.
      MiniMed Fit: Everything a tubeless pump should be.

      MiniMed Fit™ marks a significant expansion of the company's insulin delivery portfolio, bringing its advanced automated insulin delivery technology to a tubeless design for the first time. With up to twice the wear time of other tubeless options* and 50% more insulin capacity,† the system reduces the number of pump changes and daily decisions, so there is less to do and less to think about with diabetes management.

      "People with diabetes shouldn't have to choose between the freedom of tubeless wear and the health outcomes they deserve," said Que Dallara, chief executive officer of MiniMed. "MiniMed Fit™ brings the technology people trust from MiniMed into a tubeless design that fits their lives. Clearing FDA ahead of schedule is more proof we're executing our strategy. It puts MiniMed Fit in U.S. customers' hands sooner, and the pharmacy channel makes it easier to get."

      Everything a tubeless pump should be

      MiniMed Fit™ is designed to automate more of the work of diabetes management and reduce interruptions in daily routines. It combines a discreet, waterproof tubeless pump with app control on compatible iOS and Android devices and at commercial launch will offer the choice of two all-in-one sensors: Simplera Sync™ with up to seven days of wear and Instinct™, made by Abbott, with up to 15 days of wear.

      • Fewer changes. More freedom. With up to seven days of wear and 300-unit insulin capacity, MiniMed Fit™ offers up to twice the wear time and more insulin than other tubeless insulin pump options, meaning fewer pump changes and more time to focus on what matters. *†‡
      • Automation every five minutes. Powered by SmartGuard™ technology, the system automatically adjusts insulin delivery and can deliver correction doses every five minutes.§ 
      • Easier mealtimes. With Meal Detection™ technology, the system can deliver additional insulin when a meal dose is sometimes missed or underestimated. §‖
      • More time in range, day and night. Real-world users of SmartGuard™ technology have achieved up to 80% Time in Range and 91% overnight Time in Range with recommended settings, helping people spend more time in their target glucose range. ¶ #**1,2
      • Flexible wear locations and insulin compatibility. Wear locations are back of arm, lower back, upper buttocks, abdomen, and thigh. Compatible insulins are Humalog, NovoLog, and Admelog.
      • Easier access through the pharmacy. MiniMed Fit™ will be available through the pharmacy channel, offering a convenient way for people to access.
      • Built for what's next. MiniMed Fit™ is designed for future innovation, including the planned integration with MiniMed's next-generation fully closed-loop technology (investigational).

      The MiniMed Fit™ launch is expected to begin with a phased rollout in the U.S. in spring 2027, following an early customer experience phase expected to begin in MiniMed's fourth quarter of fiscal year 2027.

      In preparation for launch, MiniMed has been building manufacturing capacity and commercial infrastructure alongside the regulatory process. The company plans to significantly expand manufacturing capacity as commercialization progresses to support growing demand and capitalize on a new growth opportunity in tubeless insulin pumps.

      MiniMed Fit™ is cleared for people with Type 1 and Type 2 diabetes ages 7 and older. People interested in learning more about MiniMed Fit™ availability can request to receive updates at minimed.com/fit.

      About MiniMed 
      MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes. 

      Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. 

      Footnotes & References

      *Tandem Mobi can be worn up to 7 days with a required cartridge change at 3 days. Omnipod can be worn up to 3 days. Mint has 3-day wear, plus a 12-hour grace period for insulin delivery. See user guides for more details.

      † Omnipod, Mint, and Mobi tubeless devices hold 200 units. See product IFUs for details.

      ‡ 7-day wear achievable with less than 42 units of total daily dose. Total daily dose may impact frequency of changes.

      § Refers to SmartGuard™ feature. Individual results may vary.

      ‖ Taking a bolus 15–20 minutes before a meal helps to keep blood sugar levels under control after eating.

      ¶ Due to inherent real-world data limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.

      # Real-world evidence. N=101,629. 86.3% users achieved >70% Time in Range

      ** Overnight period: 12:00 AM- 6:00 AM. Number of users with ≥10 days of sensor glucose data; Optimal settings are glucose target at 100 mg/dL (5.5 mmol/L) and Active Insulin Time (AIT) at 2 hours and used >95% of the time.

      ∞ Pump is waterproof up to 8 feet (2.4 meters) for 1 hour and 45 minutes. If you choose to stay connected while in water, CGM readings may not be transmitted to the pump.

      1. Choudhary P, et al. Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence. Diabetes Technol Ther. 2024;26 (Suppl. 3):S32-S37.15

      2. McVean JJF, Niu F, Liu M, et al. Automated insulin delivery with the MiniMed™ 780G system reduces burden by improving sleep and glycaemic control overnight. Diabetes Obes Metab. 2026;28(3):2456-2460. doi:10.1111/dom.70380

      SOURCE MiniMed

      Modal title

      Also from this source

      MiniMed to Participate in Upcoming Investor Conferences

      MiniMed to Participate in Upcoming Investor Conferences

      MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Chad Spooner, EVP, Chief Financial Officer, will discuss and...

      MiniMed to Announce Its Fiscal Year 2027 Second Quarter Financial Results

      MiniMed to Announce Its Fiscal Year 2027 Second Quarter Financial Results

      MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that it expects to report financial results on Tuesday, November 24,...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Medical Equipment

      Medical Equipment

      FDA Approval

      FDA Approval

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.